Nanoscope Therapeutics was recently singled out for its ground-breaking optogenetics drug at the OIS Retina Innovation Summit in New York, the latest achievement in the company’s quest to restore meaningful vision to the millions of us suffering from debilitating retinal diseases.
Since announcing the remarkable results of its Phase 1/2a clinical trial for Retinitis Pigmentosa last June, the company has been on a tear — launching a Phase 2b clinical trial for RP as well as a Phase 2 clinical trial for Stargardt disease. Results from both of these trials will be announced first quarter of 2023. I have been watching Nanoscope closely over the past year because as far as I can tell, it offers the best hope for vision restoration in those of us living with late-stage RP — regardless of gene mutation. I had the opportunity to interview both CEO, Sulagna Bhattacharya, and President, Samarendra Mohanty, and was moved by their incredible passion and commitment, which at this point has been decades in the making.
To read more about Nanoscope’s remarkable results in their Phase 1/2a trial in India, click here.
For a deep dive into the decades-long journey behind this game-changing drug, click here.
Thanks for sharing this exciting news and source of hope!